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Abstract
Malignant melanoma (MM) is an aggressive cutaneous malignancy associated with poor prognosis; many putatively
therapeutic agents have been administered, but with mostly unsuccessful results. Propionibacterium acnes (P. acnes) is an
aerotolerant anaerobic gram-positive bacteria that causes acne and inflammation. After being engulfed and processed by
phagocytes, P. acnes induces a strong Th1-type cytokine immune response by producing cytokines such as IL-12, IFN-c and
TNF-a. The characteristic Th2-mediated allergic response can be counteracted by Th1 cytokines induced by P. acnes
injection. This inflammatory response induced by P. acnes has been suggested to have antitumor activity, but its effect on
MM has not been fully evaluated. We analyzed the anti-tumor activity of P. acnes vaccination in a mouse model of MM.
Intratumoral administration of P. acnes successfully protected the host against melanoma progression in vivo by inducing
both cutaneous and systemic Th1 type cytokine expression, including TNF-a and IFN-c, which are associated with
subcutaneous granuloma formation. P. acnes-treated tumor lesions were infiltrated with TNF-a and IFN-c positive T cells. In
the spleen, TNF-a as well as IFN-c producing CD8
+T cells were increased, and interestingly, the number of monocytes was
also increased following P. acnes administration. These observations suggest that P. acnes vaccination induces both
systemic and local antitumor responses. In conclusion, this study shows that P. acnes vaccination may be a potent
therapeutic alternative in MM.
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Introduction
Malignant melanoma (MM) is a life-threatening disease that is
commonly resistant to treatment. Early diagnosis followed by
surgical resection improves the prognosis of patients with MM.
However, despite careful follow-up and treatment with combina-
tion chemotherapy or adjuvant therapy, patients with MM
frequently develop both local and distant metastases. Patients
with distant metastases almost always have a poor clinical
outcome. Due to the high frequency of spontaneous recurrence
of MM lesions, adjuvant therapy is generally recommended.
Starting with Coley toxins more than one hundred ago, adjuvant
therapy or immunotherapy has come to be regarded as one of the
effective methods for boosting anti-tumor immunity [1], and
various compounds and therapeutic modalities have been tested
against melanoma using experimental mouse models [2,3,4].
However, the precise mechanisms driving the response have not
been elucidated.
Propionibacterium acnes (P. acnes) is a component of the normal
bacterial flora of the skin; it is aerotolerant, anaerobic gram-positive
bacteria that plays an important role inthe pathogenesisof acne[5].
When dendritic cells (DC) phagocyte and process P. acnes,a
powerful Th1-type cytokine immune response is elicited, leading to
an increased production of IL-12, IFN-c and TNF-a. Injection of P.
acnes has been reported to shift a dominant Th2 response to a Th1
type response, with an associated improvement in skin symptoms
[6]. Clinically, acne vulgaris, a P. acnes-associated disease, often
occurs in patients after a recovery from severe atopic dermatitis [7].
In the present study, we developed a mouse model of MM and




Animal care was performed according to standard ethical
guidelines, and all of the experimental protocols were approved by
the Institutional Board Committee for Animal Care and Use of
Mie University (Permit Number 21-27-1).
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Female C57BL/6J(B6) mice were purchased from Japan SLC
Co. (Shizuoka, Japan) and were bred under specific-pathogen-free
conditions.
P. acnes
P. acnes was purified from normal healthy volunteers and
cultured in brain-heart infusion medium supplemented with L-
cysteine and Tween-80, as reported previously [8]. Cultured
bacteria were washed with sterile distilled water, killed by heating
at 60uC for 60 min, and then lyophilized. A strain of P. acnes that
effectively promotes inflammatory cytokine production was
selected (P. acnes-Mie1) and used in the subsequent experiments [9].
Melanoma cell and injection
The B16 melanoma cell line was purchased from ATCC
(Manassas, VA), and cultured in RPMI-1640 (Sigma-Aldrich, St.
Louis, MO) containing 10% fetal bovine serum (HyClone
Laboratories, INC., South Logan, UT) at 37uC in a humidified
incubator containing 5% CO2 and 95% air. 1610
6 melanoma
cells were injected in the dorsal skin of 8 week-old mice.
Vaccination schedule
3.3 mg of heat-killed P. acnes were injected into the dorsal skin at
the site where MM cells had been injected in 8–10 week old mice.
Mice were divided into five groups: 1) MM-bearing mice treated
with PBS (20 ml (MM, n=14), 2) a group of MM-bearing mice
treated with P. acnes at 10 weeks old (PMM1, n=15), 3) another
group treated with P. acnes-treated at 8 and 10 weeks old (PMM2,
n=15), 4) a control group of mice treated with P. acnes (P1, n=11)
at 10 weeks old, and 5) another control group treated with P. acnes
at 8 and 10 weeks old (P2, n=13).
Clinical manifestations and histopathological study
Tumor growth was measured by the longest (L) point and the
perpendicular diameter (W) of the dorsal skin tumor mass at 12
weeks of age, and the tumor volume was calculated according to
the following formula: 4pW
2L/3 [10]. The tumor tissue, lung,
liver, and spleen were excised from the animals of each group, and
samples were embedded in paraffin to prepare sections for
haematoxylin & eosin staining.
Analysis of cytokine mRNA expression
The RNA was extracted from skin lesions using Isogen (Nippon
Gene, Tokyo, Japan) according to the manufacturer’s instructions
and as reported previously [9,11]. Briefly, 1 ml of homogenate was
mixed with 200 ml of chloroform and then centrifuged. The
aqueous phase was separated and mixed with 0.5 ml of 2-propanol
(Nakalai Tesque, Kyoto, Japan) to precipitate RNA. After
centrifugation, the precipitate was washed with 70% ethanol
(Nakalai Tesque) and the RNA was suspended in 40 ml RNase-free
water. The RNA concentration was measured at 260 nm, and the
quality was confirmed by electrophoresis. cDNA was synthesized
from 2 mg of RNA using an Archive Kit (ABI, Foster City, CA,
USA) according to the manufacturer’s protocol. Real time
quantitative reverse transcription-polymerase chain reaction
(RT-PCR) was performed to determine the transcriptional activity
in the tumor lesions. A 25-ml reaction mixture containing 1 mgo f
cDNA, 900 nmol of each primer, and 250 nmol of TaqMan probe
was mixed with 12.5 ml of TaqMan Master Mix (ABI).
Quantitative RT-PCR for cytokine transcripts was performed
using prequalified primers and probes corresponding to IFN-c T-
bet, IL-12p35, IL-12p40, TNF-a IL-17A, IL-10, MIP-2, and
GAPDH (ABI). The DdCt method was used to standardize the
transcripts to GAPDH.
Cell isolation and preparation from spleen and skin
tumor tissue
The spleens were sampled and single cell suspensions was
prepared by mechanical mincing, as reported previously [6]. For
the characterization of tumor infiltrating lymphocytes (TIL), skin
tumor tissue from the dorsal region was removed, minced gently
with scissors and then single cell suspensions were prepared. After
passing through a 70-mm-pore mesh, the cells were washed and
resuspended with PBS. After Ficoll (SIGMA, St. Louis, MO)
separation, cells were washed and resuspended in RPMI1640
medium containing 10% FBS.
FoxP3 intracellular Staining
The spleen cells were initially stained with FITC-labeled anti-
mouse CD4 antibody and PE/Cy5 anti-CD25 antibody, and then
fixed in FoxP3 Fix/Perm solution (BioLegend); the cells were then
stained with PE conjugated anti-mouse FoxP3 antibody (BioLe-
gend). The fluorescence profile was analyzed by flow cytometry
using FACSCalibur (BD Biosciences, San Jose, CA).
In vitro stimulation for cytokine production
Spleen cells were seeded at 2610
6 cells/ml (1 ml/well) and
cultured in 24-well plates (Costar, NY, USA) in RPMI 1640
medium containing 10% (v/v) FBS (5% of the murine serum was
used for IL-10 analysis), 2.0 mM L-glutamine, 100 U/ml penicillin,
and 100 mg/ml streptomycin. TIL cells were cultured in 96-well
culture plates (Costar) under the same conditions. Cells were
stimulated with 1 mg/ml ofanti-mouse CD3e (BD Pharmingen,San
Jose, CA), 2 mg/ml anti-mouse CD28 (BD Pharmingen) and 1 mg/
ml brefeldin A (Biolegend, San Diego, CA). The cells were
incubated for 8 h at 37uC under a 5% CO2/95% air atmosphere.
Flow cytometric immunofluorescence analysis
The cell surface antigen and the intracellular cytokines were
stained according to the formal Cell Surface Immunofluorescence
Staining Protocol and Intracellular Cytokine Staining Protocol
(BioLegend), as previously reported [6,11]. Briefly, for the
detection of IFN-c, IL-17, IL-10 and TNF-a, the cells were first
stained with PE anti-mouse CD8 and PE/Cy5 anti-mouse CD3e
antibodies (BioLegend). After treatment with the fixation buffer
(BioLegend) and the permeabilization wash buffer (BioLegend),
cells were stained with FITC-conjugated anti-mouse IFN-c, IL-
17A, IL-10 and TNF-a antibodies (BioLegend). For the charac-
terization of monocytes, the cells were similarly stained with PE-
conjugated anti-mouse CD14 monoclonal antibody, followed by
intracellular cytokine staining. The fluorescence profiles were
analyzed by flow cytometry using FACSCalibur.
Statistical analyses
Statistical analysis was performed by using the Kruskal-Wallis
nonparametric analysis of variance with post hoc analysis using the
Dunn multiple comparison test. A P-value of less than 0.05 was
considered to be statistically significant.
Results
Cutaneous manifestations ,Dramatic regression of the
tumor by P. acnes treatment,
We assessed the tumor size 4 weeks after the injection of the B16
melanoma cells. PBS-treated control mice (MM) had developed
P. acnes Vaccination Suppresses Malignant Melanoma
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bearing mice, PMM1 and PMM2, was significantly smaller than in
the control mice (Fig. 1A, B).
Histopathological findings
In the MM control mice, melanoma cells proliferated massively
in the subcutaneous region and invaded the underlining muscular
layers. Inflammatory cell infiltration was sparsely detected both
inside and around the tumors (Fig. 1B). In contrast, histopatho-
logical study in PMM1 revealed subcutaneous granuloma
formation with only a small number of melanoma cells around
the muscular layer. In PMM2, there was enhanced granuloma
formation and mononuclear cell infiltration compared with that
detected in PMM1. Surprisingly, melanoma cells were almost
undetectable in PMM2. No distant melanoma cell metastasis was
detected.
Flow cytometric analysis of spleen cells
The percentage of CD14
+ monocytes in the total number of
spleen cells was significantly increased in PMM2 and PMM1
compared with the MM and control groups. This increase was also
observed in the P. acnes-treated control mice (P1 and P2) (Fig. 2A).
Figure 1. Tumor size, clinical phenotype, and histological findings. A. Tumor size at the end of observation period: 4 weeks after B16
melanoma implantation. PBS-treated control mice (MM) developed a large tumor. Treatment with P. acnes led to a significant decrease of tumor size
in both PMM1 (p,0.01) and PMM2 (p,0.001). B. i) Clinical picture of the tumors implanted on the dorsal skin. ii) Massive melanoma cell proliferation
in the subcutis with invasion of the surrounding muscular tissues in MM. By contrast, PPM1 and PMM2 displayed subcutaneous granuloma formation
(640). iii) Close up of the upper dermis (6200). iv) Close up of the muscular tissue levels (6200). In MM mice, melanoma cell growth was observed
without inflammatory cell infiltration. In PMM1 mice, melanoma cells were detected around the muscular lesion, but melanoma cells were almost
undetectable, and abundant mononuclear cell infiltration was found in the PMM2 mice.
doi:10.1371/journal.pone.0029020.g001
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+ T cells among
the total number of CD4
+ and CD8
+ T cells were significantly
elevated in PMM2 mice compared with MM and control mice
(Fig. 2B). CD8
+IFN-c
+ T cells were also increased in the P1 and
P2 groups. Similar results were observed in TNF-a expressing
CD8
+ T cells (Fig. 2C). The ratio of IL-17
+CD4
+ (Th17) cells and
IL-10
+CD4
+ (Tr1) cells among the total number of CD4
+ cells




(iTreg) cells was also not changed by P. acnes treatment (Fig. 2D).
Cytokine mRNA expression in skin lesions
Quantitative RT-PCR was performed to investigate the
cytokine mRNA expression in the tumor lesions. The RNA
expression of IFN-c T-bet, IL-12p35, TNF-a and MIP2 was
significantly increased in PMM2 and P2 mice compared with the
MM group. No significant change was found in the mRNA
expression of IL-12p40, IL-17 or IL-10 among the six groups
(Fig. 3).
Characterization of tumor infiltrating lymphocytes





+ cells were detected





+ cells. On the other hand, Th17 and Tr1 cells were fewer
in the TILs. The number of infiltrating cells was very limited in
non-treated MM and could not be assessed.
Discussion
In the present study, the effects of intra-tumor P.acnes
vaccination (ITPV) on the growth of melanoma skin lesions was
evaluated, and found that the growth of seeded melanoma cells
was suppressed. ITPV successfully controlled melanoma progres-
sion in vivo by an induction of Th1 type cytokines, including TNF-
a and IFN-c in both the skin and the systemic circulation. The
clinical benefit of vaccination was associated with subcutaneous
granuloma formation. Tumor cells were not detected in the
granulomas. The measured tumor size was significantly decreased
in the vaccine-treated group compared with the control groups.
The tumor size may have been underestimated because of the
granuloma volume. However, granuloma formation is an
immunological event that is related to augmented phagocytic
activity as well as cellular cytotoxic activity. Granuloma formation
thus plays an important role in effective anti-tumor immunother-
apy. In the present study, we found that ITPV promotes the
activation of TNF-a and IFN-c producing cells in the skin tumor
lesions. IL-12, TNF-a and IFN-c are known to be effective anti-
tumor cytokines. However, individual cytokines are reported to
exert only limited clinical effects, and thus they have been most
commonly used in combination with chemotherapy. Unlike the in
vitro study results, the effect of recombinant cytokine therapy in vivo
is limited, in large part due to the very short biological half-life of
recombinant cytokines. A branched-chain polyethylene glycol
moiety attached interferon alfa-2a (peginterferon alfa-2a) has been
used to prolong the biological half-life [12]. Previous studies have
shown that P. acnes enhances the anti-tumor activity of monocytes/
macrophages [13,14,15] and the tumoricidal function of NKT and
NK against melanoma [15]. In ITPV, P. acnes is phagocytosed and
processed by monocytes/macrophages, which are present inside
and around the tumors, and the persistent secretion of cytokines
and chemokines from these cells leads to granuloma formation.
IL-12 is an antitumor cytokine that activates NK and cytotoxic T
cells,therebypromotingstronganti-tumoractivitybyinducingIFN-
c [16,17]. In the present study, we found increased local expression
of IL-12p35 in ITPV. IL-12 is a heterodimeric cytokine containing
IL-12p35 and IL-12p40 that binds to a specific receptor. On the
other hand, free IL-12p40 forms sulfide-linked homodimers that
block IL-12 function both in vitro and in vivo [18]. Enhanced
expression of IL-12p35, but not IL-12p40, is suggested to have the
potential to exert favorable therapeutic effects against tumors.
P. acnes binds to TLR2 on monocytes and dendritic cells, leading
to activation of the IL-12 promoter [19]. IL-12 activates STAT-4
and T-bet transcription factors in T cells and NK cells. T-bet
binds to the IFN-c gene promoter and increases the production of
IFN-c [7]. In this study we found that IFN-c induces cytotoxic
effects by activating CD8
+ T cells, NK cells and B cells. It also
induces chemokines, including CXCL9 (MIG) and CXCL10 (IP-
10) that suppress vascular proliferation.
Recombinant IL-12 has been used as an anti-cancer therapy,
but with unsuccessful results, eliciting systemic side effects and only
limited clinical benefit. Local administration of IL-12 for
therapeutic purposes has been suggested to improve the outcome
in certain cancers. To limit the expression of IL-12 and prolong
local IL-12 secretion, IL-12 plasmid vaccination has been
administered for metastatic melanomas [20]. In this regard, ITPV
has the advantage of persistently inducing IL-12 expression at the
site of injection; this is followed by infiltration of TNF-a and IFN-c
producing T cells into the lesions, resulting in tumor suppression.
Granuloma formation is a characteristic feature of P. acnes
vaccination, with the accumulation of monocytes being required
for this activity. Potent IFN-c expression occurs after P. acnes
administration and leads to granuloma formation. Granuloma is a
persistent source of Th1 type cytokines in vivo. An increase in MIP2
(CXCL2) was detected in P. acnes-treated skin lesions. This
chemokine is secreted by monocytes and macrophages, and is
chemotactic for polymorphonuclear leukocytes and hematopoietic
stem cells. MIP2 is one of the chemokines involved in granuloma
formation. On the other hand, granuloma formation and
ulceration have been considered as side effects in systemic anti-
cancer vaccine trials. Since melanoma is a cutaneous malignancy,
no special technique is required for accurate intralesional
administration of the vaccine. Accumulated phagocytes in the
granuloma may additionally contribute to the effective removal of
tumor cells in combination with cytotoxic lymphocytes. Based on
these observations, granuloma or ulceration is still considered to be
relevant to successful cutaneous tumor immunotherapy.
In addition to its local effects, ITPV may also exert systemic
anti-tumor activity. After ITPV, TNF-a and IFN-c producing
Figure 2. Intracellular cytokine and Foxp3 expression in spleen cells. A, Phenotypical analysis: the ratios of the CD4
+ T cells to total
lymphocytes, CD8
+ T cells to total lymphocytes and CD14
+ monocytes to total splenic mononuclear cells are shown. The percentage of CD14
+





+ T cells among the total CD4
+ and CD8
+ T cells, respectively. In PMM2 mice, the percentage of both populations was
significantly elevated compared to the MM and control mice. CD8
+IFN-c





+ T cells and TNF-a
+ monocytes among the total CD4
+, CD8
+ T cells, and monocytes, respectively. In PMM2
mice, the percentage of TNF-a
+CD8
+ T cells was significantly elevated compared to MM. TNF-a
+CD8
+ T cells were also increased in the P2 group. D,
The percentages of Th17, Tr1 and iTreg in CD4
+ T cells. The percentages of IL-17
+CD4
+ (Th17) cells and IL-10
+CD4
+ (Tr1) cells among the total CD4
+
cells, and the ratios of the Foxp3
+CD4
+CD25
high T cells (iTreg) to CD4
+ T cells, were unchanged by P. acnes treatment.
doi:10.1371/journal.pone.0029020.g002
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+ T cells were increased in the spleen and skin. However,
melanoma-specific cytotoxicity of CD8 T cells was not increased
in the spleen or draining lymph nodes in P. acnes injected
melanoma-bearing mice (Fig. S1), suggesting that most of the
cytotoxic CD8 T cells may be recruited into the injected skin
lesions. Consistent with the previous reports [21,22], the number
of splenic monocytes was also increased by ITPV. The role of the
systemic immune response in the mechanism of distant metastasis
remains unclear. Previous studies have suggested that augmenta-
tion of anti-tumor cytokine expression in spleen cells have
preventive effects against distant metastasis.
In the present study, mice received either a single dose or two
doses of vaccination. We injected P. acnes on day 0 and/or on day
14 into the cutaneous tumor lesions. Even the single therapy on
Figure 3. Cytokine mRNA expressions in the skin lesions. Quantitative RT-PCR was performed to determine the cytokine mRNA expression in
the tumor lesions. The IFN-c T-bet, IL-12p35, TNF-a and MIP2 mRNA levels in PMM2 and P2 mice were significantly increased compared to MM mice.
No significant change was found in the IL-12p40, IL-17 or IL-10 mRNA levels among the six groups of mice.
doi:10.1371/journal.pone.0029020.g003
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However, priming on day 0 followed by a second vaccination on
day 14 resulted in a more potent growth inhibitory activity
compared to the single vaccination. Early intervention before full
tumor development may have the advantage of inducing
enhanced Th1 type anti-tumor activity compared to vaccination
after established melanoma growth. A second vaccination induced
a booster effect on the activation of the cytokine network.
Th17, Tr1 and iTreg cells play critical roles in the regulation of
the immune system. In the present study, P. acnes vaccination
shifted the Th1/Th2 balance toward a dominant Th1 immune
response. Th17 is involved in Th1-associated diseases such as
psoriasis. However, we found no changes in the protein or RNA
expression of IL-17 in the present immunotherapy, as IL-17 was
undetectable in TIL. Therefore, it is unlikely that Th17 was
involved in the beneficial effect of P. acnes vaccination therapy.
Tr1 and iTreg cells are known to regulate the inflammatory
response. Tr1 regulatory cells produce IL-10 and play a critical
role in the suppression of allergic diseases [11,23]. It was reported
that P. acnes therapy increases iTreg cells by stimulating TLR2 in





+ T cells were also present in the tumor. By contrast, very few Th17 cells or Tr1 cells were detected in TILs.
The number of infiltrating cells in the non-treated melanoma tumors was very limited, and thus was not analyzable. Representative results from five
experiments are shown.
doi:10.1371/journal.pone.0029020.g004
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cells has been associated with successful cancer immunotherapy
[25]. Interestingly, neither Tr1 cells nor iTreg cells were elevated
in the present study, suggesting that they are not involved in the
mechanistic effect of this therapy. Unlike allergic mice, which have
a Th2 dominant response, cancer-bearing mice may have different
immunological backgrounds in response to P. acnes vaccination.
Further investigation is required to clarify the precise mechanism
of the P. acnes mediated immune responses.
In conclusion, the results of this study showed that ITPV
successfully suppresses MM, and that the beneficial effect of this
therapy depends on the induction of granuloma formation along
with the secretion of IL-12, IFN-c and TNF-a. Further
investigation is required before this treatment comes into use in
clinical practice. P. acnes vaccine is a promising candidate as an
adjuvant therapy of melanoma.
Supporting Information
Figure S1 The cytotoxicity of CD8
+ T cells prepared
from spleen or draining lymph node was analyzed using
three methods. The first method is chromium release assay, and
the second is viability detection by flow cytometry using Live/
Dead cell-mediated cytotoxicity kit (Molecular probes, Carlsbad,
CA). Finally DHL cell cytotoxicity assay kit (AnaSpec Corporate
Headquarter, San Jose, CA) was used to detect the release of
Lactate Dehydrogenase (LDH) from targeted melanoma cells.
Spleen and draining lymph node samples were taken from
melanoma and P. acnes-injected mice: melanoma cell was free in
the dorsal skin, P. acnes only injected mice, and normal control
mice. Single cell suspensions were prepared by mechanical
mincing, and after passing through a 70-mm-pore mesh, the cells
are washed and resuspended in PBS. After Ficoll separation, the
cells were washed and resuspended in RPMI1640 medium
containing 10% FBS. CD8 T cells were purified using magnetic
beads, and co-cultured with B16 melanoma cells at three different
effector cell/target cell ratio (12.5:1, 25:1, 50:1) according to
previous reports. Chromium release assay A, 6 hours incubation
LN CD8 T cells. B, 6 hours incubation splenic CD8 T cells. C,
15 hours incubation LN CD8 T cells. D, 15 hours incubation
splenic CD8 T cells. When there was injury of targeted melanoma
cells, chromium was released. Analysis of apoptotic melanocytes
using live/dead viability detection system by flow cytometry E,
8 hours incubation LN CD8 T cells. F, 8 hours incubation splenic
CD8 T cells. Analysis of lactate dehydrogenase (LDH) released
from targeted melanoma cells G, 8 hours incubation LN CD8 T
cells H, 8 hours incubation splenic CD8 T cells. Melanoma and P.
acnes-injected mice:N, P. acnes only injected mice: &, and normal
control mice: m. CD8 T cells melanoma-specific cytotoxicity was
not increased in P. acnes injected melanoma-bearing mice,
suggesting that most cytotoxic CD8 T cells was recruited into
the injected skin lesions.
(TIFF)
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